Authors say that screening based on individual life expectancy, rather than age, may improve screening selection and value<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Dec. 6, 2023 (HealthDay News) — Personalized colorectal cancer (CRC) screening based on individual life expectancy may increase the value of CRC screening programs, according to a study published online Oct. 27 in the\u00a0American Journal of Gastroenterology<\/em>.<\/p>\n Po-Hong Liu, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues examined receipt of past-year CRC screening according to predicted 10-year mortality risk among 25,888 community-dwelling, older adults (ages 65 to 84 years) who were not up-to-date with screening.<\/p>\n The researchers found that the prevalence of past-year CRC screening was 39.5, 40.6, 38.7, 36.4, and 35.4 percent from the lowest to highest quintile of 10-year mortality risk. There were no significant differences observed in the odds of CRC screening between adults in the lowest versus highest quintile (adjusted odds ratio, 1.05; 95 percent confidence interval, 0.93 to 1.20). More than one-quarter (27.9 percent) of past-year CRC screening occurred in adults with life expectancy <10 years. Furthermore, at the time of screening, more than half of adults aged 75 to 84 years (50.7 percent) had 10-year mortality risk \u00e2\u0089\u00a550 percent.\u00a0<\/p>\n “An age-based approach to CRC screening results in underscreening of older, healthier adults and overscreening of younger adults with chronic conditions,” the authors write.<\/p>\n One author disclosed ties to Exact Sciences, Universal Dx, Roche, and Freenome.<\/p>\n Abstract\/Full Text\u00a0(subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n